ATC Group: L04AJ03 Pegcetacoplan

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L04AJ03 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L04 Immunosuppressants
3 L04A Immunosuppressants
4 L04AJ Complement inhibitors
5 L04AJ03

Active ingredients in L04AJ03

Active Ingredient Description
Pegcetacoplan

Pegcetacoplan is a symmetrical molecule comprised of two identical pentadecapeptides covalently bound to the ends of a linear 40-kDa PEG molecule. The peptide moieties bind to complement C3 and exert a broad inhibition of the complement cascade. The 40-kDa PEG moiety imparts improved solubility and longer residence time in the body after administration of the medicinal product. It is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor.

Related product monographs

Title Information Source Document Type  
ASPAVELI Solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Estonia (EE)

France (FR)

Ireland (IE)

Italy (IT)

Lithuania (LT)

Poland (PL)

Romania (RO)

Spain (ES)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.